Experience Leucine AI.
Powered Pharma Operations

Transform Your Pharma Operations with AI-Powered Intelligence. Experience how Leucine's integrated platform brings together manufacturing, quality, and laboratory operations in one digital ecosystem. Schedule a personalized demo to see how our AI solutions can optimize your processes, ensure compliance, and drive operational excellence.

See How AI Transforms Your Shop Floor Operations.
Experience firsthand how Leucine's 10x MES digitalizes batch records, streamlines production, and provides real-time monitoring of your manufacturing operations. Schedule a personalized demo to discover how our AI-powered platform can enhance your productivity while maintaining compliance.

Experience AI-Driven Quality Management in Action.
See how Leucine's 10x QMS automates compliance workflows, streamlines change control, and ensures regulatory adherence. Schedule a demo to learn how our AI-powered platform can help you manage quality processes more efficiently while reducing compliance risks.

Discover Smart Laboratory Operations Management.
Watch how Leucine's 10x LES orchestrates your lab operations, automates documentation, and ensures data integrity. Schedule a demo to see how our AI-powered platform can accelerate your testing processes while maintaining audit-readiness.

Optimize your manufacturing processes with paperless operations
Strengthen quality management and regulatory compliance
Accelerate laboratory operations and testing workflows

Connect with a Leucine Expert

Schedule a 30-Minute Product Demo with Expert Q&A

Sub System
Document Management

Document Management

View Detailed Analysis

Analytics Overview

115
Form 483s Issued
12
483s converted to WL
182
Total Observation
Form 483s Issued
+74 from last period

Analytics Overview

Form 483 Conversion Rate by Year
Form 483s Issued (Yearly)

Recent Form 483s & Warning Letters

View all 483’s
Issue Date
Facility Name
Product Type
Form 483
Converted
Warning Letter
27 Sep 2024
Biocon Sdn Bhd
Drugs
20 Sep 2024
Aarti Drugs Limited
Drugs
06 Sep 2024
Annovex Pharma, Inc.
Drugs
06 Sep 2024
Granules India Limited
Drugs
06 Sep 2024
Granules India Limited
Drugs

Top Investigators

Investigator Name
Form 483 Count
Warning Letter Count
Justin A Boyd
21
4
Pratik S Upadhyay
14
2
Arsen Karapetyan
11
0
Margaret M Annes
8
2
Anastasia M Shields
7
2
TITLE/ COMPANY Issue Date Status Details
Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records are instituted by authorized personnel.
Biocon Sdn Bhd
27 Sep 2024 Normal Justification: Document management issues are highlighted by the lack of control over General Format documents used in critical processes.
Excerpt: General Format documents not controlled or reconciled; forms can attach data printouts for DEV/CAPA investigations.
View Details
Records associated with the API distribution were not readily available
Aarti Drugs Limited
20 Sep 2024 Normal Justification: The missing records are a direct result of poor document management practices, impacting data completeness and regulatory obligations.
Excerpt: Your Site Head acknowledged the missing data from the shared API list and promised to provide updated list.
View Details
Your outsourcing facility did not submit a report to FDA identifying the drugs compounded during the previous six month period.
Annovex Pharma, Inc.
06 Sep 2024 Normal Justification: Document Management is crucial as the failure stems from not managing and submitting the report properly.
Excerpt: Your outsourcing facility did not submit a report to FDA identifying the drugs compounded during the previous six month period.
View Details
The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
Granules India Limited
06 Sep 2024 Normal Justification: Faulty document management is evident by unauthorized disposal of critical GMP documents as per observation.
Excerpt: We observed three (3) trucks full of scrap materials...revealed presence of large number of torn pieces of GMP documents.
View Details
The responsibilities and procedures applicable to the quality control unit are not
Granules India Limited
06 Sep 2024 Normal Justification: Document Management is fundamentally linked owing to the mishandling and unauthorized disposal of critical GMP documents.
Excerpt: Lacks oversight on the control and management of GMP documents... three trucks full of scrap materials... torn pieces of GMP documents...
View Details

Prepare Better for FDA Audits with FDA Tracker

Get Real-time Insights: FDA 483s & Warning letters.
Uncover Trends: FDA Investigator profiles & Observations.
Stay Compliant: Manage risks proactively.